Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer
Year: 2008
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: J. Baselga, P. A. van Dam, R. Greil, H. Gardner, R. Bandaru, B. Molloy, J. Steinseifer, P. Phillips, J. M. Dixon, H. S. Rugo
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2252337940